DECA Stock Recent News

NEW YORK, NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the “Articles”) to extend the date by which the Company must consummate an initial business combination from July 11, 2024 to April 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to nine times by an additional one month each time (the “Extension”).

Drug developer Semnur Pharmaceuticals said on Tuesday it has signed a letter of intent to go public through a merger with special purpose acquisition company Denali Capital Acquisition Corp in a pre-transaction equity deal valued at up to $2 billion.

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, and Denali Capital Acquisition Corp., a Cayman Islands corporation and special purpose acquisition company (Nasdaq: DECA, “SPAC”), today announced the signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”).  The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”).  The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.

NEW YORK, NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that an aggregate of $50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an additional month from June 11, 2024 to July 11, 2024 in accordance with the amended terms of the Company's amended and restated memorandum and articles of association.

NEW YORK, NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that an aggregate of $50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an additional month from May 11, 2024 to June 11, 2024 in accordance with the amended terms of the Company's amended and restated memorandum and articles of association.

NEW YORK, NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that an aggregate of $50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an additional month from April 11, 2024 to May 11, 2024 in accordance with the amended terms of the Company's amended and restated memorandum and articles of association.

NEW YORK , March 11, 2024 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the "Company") announced today that an aggregate of $50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an additional month from March 11, 2024 to April 11, 2024 in accordance with the amended terms of the Company's amended and restated memorandum and articles of association. About the Company Denali Capital Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

NEW YORK , Feb. 9, 2024 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the "Company") announced today that an aggregate of $50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an additional month from February 11, 2024 to March 11, 2024 in accordance with the amended terms of the Company's amended and restated memorandum and articles of association. About the Company Denali Capital Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.